Novartis pelabresib combination shows sustained clinical effects at 144 weeks in Phase III myelofibrosis trial
NVS•Novartis said data scheduled for December 13 show sustained clinical effects with pelabresib and ruxolitinib in previously untreated myelofibrosis patients at 144 weeks in a Phase III trial.
1. Conference data preview
Novartis said it will present nearly 60 abstracts at the 2026 San Antonio Breast Cancer Symposium and American Society of Hematology meeting. Pelabresib data scheduled for December 13 show sustained clinical effects with ruxolitinib in previously untreated myelofibrosis patients.




